Catalyst Biosciences Return on Equity

Catalyst Biosciences (CBIO) currently reports a ROE of -76.25%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Catalyst Biosciences's ROE history and peer comparisons.

Catalyst Biosciences's ROE of -76.25% is lower than the Healthcare sector average of 20.77%. That is roughly 467.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Catalyst Biosciences's current -76.25% should be judged against Healthcare norms (sector average: 20.77%) and against CBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -76.25%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Catalyst Biosciences, and consider following CBIO for alerts when major investors trade the stock.

Catalyst Biosciences is classified in the Healthcare sector. On ROE, it currently shows -76.25% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBIO with unrelated industries.